4 trends in drug/device decision-making
The health care landscape has changed immeasurably in the past few years. As such, the ways in which health systems measure the value of drugs and devices has evolved in turn.
To better understand how provider organizations are changing the way they define and determine a product’s value, The Advisory Board surveyed over 80 leaders from health system value analysis and pharmacy and therapeutics (P&T) committees. These individuals are on the front lines of product review.
Review the results to discover four ways that health systems will update their drug/device decision-making in coming years.